cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
The Mumbai-Nagpur Expressway, or Samruddhi Mahamarg (officially known as Hindu Hruidaysamrat Balasaheb Thackeray Maharashtra Samruddhi Mahamarg) and Maharashtra Expressway-2 (ME-2), is an existing operational 6-lane wide (expandable to 8), 701-km long access-controlled expressway in the Maharashtra state of India, connecting the Maharashtra's two capital cities, Mumbai in the Marathwada region in the west and Nagpur in the Vidarbha region in the east. By reducing Nagpur-Mumbai travel time to 8 hours, the expressway has boosted the economic development by providing the enhanced connectivity. It is the second expressway in the state of Maharashtra after the Mumbai–Pune Expressway, and the longest within the state.
=== The role of oxygen === Yeasts are facultative anaerobes meaning that they can exist in both the presence and absence of oxygen. While fermentation is traditionally thought of as an anaerobic process done in the absence of oxygen, early exposure of the yeast to oxygen can be a vital component in the successful completion of that fermentation. This is because oxygen is important in the synthesis of cell "survival factors" such as ergosterol and lanosterol. These sterols are important in maintaining the selective permeability of the yeast cell membrane which becomes critical as the yeast becomes exposed to increasing osmotic pressure and levels of alcohol in the wine. As a waste product of its own metabolism, alcohol is actually very toxic to yeast cells. Yeast with weak survival factors and lacking sterols may succumb to these conditions before fermenting a wine to complete dryness, leaving a stuck fermentation. Cultured yeasts that are freeze-dried and available for inoculation of wine must are deliberately grown in commercial labs in high oxygen/low sugar conditions that favor the development of these survival factors. One of the reasons that some winemakers prefer using inoculated yeast is the predictability of fermentation due to the high level of survival factors that cultured yeast are assured of having without necessarily needing to expose the wine to additional levels of oxygen. Winemakers using "ambient" yeasts that are resident in their winery may not have this same assurance of survival factors and may need to compensate with other winemaking techniques.
Mannich reaction, resulting in, e.g., voacamine Michael reaction (villalstonine) Condensation of aldehydes with amines (toxiferine) Oxidative addition of phenols (dauricine, tubocurarine) Lactonization (carpaine).
Sources: en.wikipedia.org
== Clinical significance == Truncation mutations in MYBPC3 stand as the primary cause of hypertrophic cardiomyopathy (HCM). To date, roughly 350 mutations in MYBPC3 have been identified, and in large part, the mutations result in protein truncation, shifts in reading frames, and premature termination codons. Genetic studies have revealed significant overlap between genotypes and phenotypes as MYBPC3 mutations can lead to various forms of cardiomyopathies, such as dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy. In patients with isolated or familial cases of dilated cardiomyopathy, MYBPC3 mutations represented the second highest number of known mutations. Furthermore, a 25-bp intronic MYBPC3 deletion leading to protein truncation is present in 4% of the population in South India and is associated with a higher risk to develop heart failure. Founder MYBPC3 mutations have been reported in Iceland, Italy, The Netherlands, Japan, France and Finland, where they represent a large percentage of cases with hypertrophic cardiomyopathy. All of them are truncating mutations, resulting in a shorter protein, lacking the regulatory phosphorylatable M motif and/or major binding domains to other sarcomeric proteins. A body of evidence indicates that patients with more than one mutation often develop a more severe phenotype, and a significant fraction of childhood-onset hypertrophic cardiomyopathy (14%) is caused by compound genetic variants. This suggests that a gene-dosage effect might be responsible for manifestations at a younger age.
chemical formula Any of various means of concisely displaying information about the chemical composition of a compound or molecule using letters, numbers, and/or typographical symbols. Chemical formulas, such as empirical and molecular formulas, can only indicate the identities and numerical proportions of the atoms in a compound and are therefore more limited in descriptive power than chemical names and structural formulas.
Maria Atalioti, Chief Inspector, Sovereign Base Areas Police, Cyprus. For services to Policing, Diversity and Inclusion in the Sovereign Base Areas. Elliott Forbes, Deputy Commissioner, Royal Anguilla Police Force. For services to Policing in Anguilla.
Sources: en.wikipedia.org
Defence Minister Judith Collins announces that the New Zealand Government will be investing NZ$12 billion in the New Zealand Defence Force over the next four years to raise defence spending to over 2 percent of GDP. Australian outdoor media company QMS acquires Oaktree Capital Management's 45 percent stake in Mediaworks New Zealand, gaining full control of the commercial radio company. 8 April: A tornado in Levin causes roofs to blow off houses, and trees and fences to fall over. Labour Member of Parliament David Parker announces he will retire from Parliament, effective next month. Climate Change Minister Simon Watts confirms that the New Zealand Government will shut down its green investment bank New Zealand Green Investment Finance. 9 April – The Grey District Council issues a boil water notice after coliforms were found in the water supply zones of Stillwater, Cobden, and Kaiata, and Escherichia coli was detected in Kaiata. 10 April – The New Zealand Parliament votes 112–11 to reject the Treaty Principles Bill. 11 April: Veterans Minister Chris Penk announces that the New Zealand Government will expand the legal definition of veterans and create a new national veterans day. Foreign Minister Winston Peters confirms plans to ease visa requirements for visitors from Pacific Islands Forum member states in July and November 2025. 16 April: The Otago and Southland Regions experience Internet and mobile outages after fibre optic cables are damaged by rodents and a contractor by accident. A fire near Paremata railway station in Porirua disrupts the Kāpiti Line.
=== Injection loop === The injection loop is a segment of tubing of known volume which is filled with the sample solution before it is injected into the column. Loop volume can range from a few microliters to 50 ml or more.
On July 16, 1945, the first atomic bomb test took place near the town of Alamogordo (New Mexico, USA). As a result of the atmospheric nuclear weapons tests carried out by the United States, the Soviet Union, France, Great Britain, and China, the Earth's atmosphere became increasingly contaminated with fission products from these tests from the 1950s onwards. The radioactive fallout landed on the earth's surface and ended up in plants and, via animal feed, in food of animal origin. Ultimately, they entered the human body and could be detected in bones and teeth as strontium-90, among other things. The radioactivity in the field was measured with a gamma scope, as shown at the air raid equipment exhibition in Bad Godesberg in 1954. Around 180 tests were carried out in 1962 alone. The extent of the radioactive contamination of the food sparked worldwide protests in the early 1960s.
== Life cycle and reproduction == "Ca. M. multicellularis" has a completely multicellular life cycle, with no known unicellular stage. The organism grows as an organised spherical consortium by increasing the size of its heterogeneous constituent cells until it has doubled in volume. Following this, the cells undergo synchronous binary fission while remaining associated with one another around the central acellular compartment, to preserve structure and function. The consortium then stretches from a spherical to elongated shape before separating into two approximately equal daughter consortia. Individual cells removed from the consortium rapidly lost viability, suggesting that its multicellular organisation is essential to its life cycle. When cells die within the consortium they do not detach from their living neighbours due to strong adhesion proteins. Magnetosomes of dead cells remain magnetic, so they can continue to contribute passively to the magnetic orientation of the consortium.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.